The global immunogenomics market was valued at USD 1.58 billion in 2025. The market is estimated at USD 1.79 billion in 2026 and is projected to reach USD 5.12 billion by 2036, at a CAGR of 11.1% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering immune repertoire and HLA technologies, clinical immunosequencing, regulation and reimbursement, mergers and divestitures, pricing, and the supplier landscape.
The market spans kits, reagents, instruments, software, and services for analyzing immune system genes and their diversity. In scope are T-cell receptor (TCR) and B-cell receptor (BCR) repertoire sequencing, including clinical immunosequencing for minimal residual disease (MRD); HLA and killer-cell immunoglobulin-like receptor (KIR) typing by next-generation sequencing (NGS), long-read sequencing, and PCR; immune gene expression profiling; single-cell profiling that pairs receptor sequences with gene expression; neoantigen and immunopeptidome analysis; and the bioinformatics needed to interpret the results. Customers range from transplant and histocompatibility laboratories and donor registries to hospital laboratories, research institutes, and drug developers.
Adaptive Biotechnologies reported second-quarter 2026 MRD revenue of USD 66.2 million, up 33%, as clonoSEQ volume rose 43% to 36,111 tests, and now guides to 2026 MRD revenue of USD 268-278 million. The company also reported Immune Medicine revenue of just USD 5.4 million in the quarter, down 40% year over year, a sign that clinical testing has commercialized far faster than repertoire data for drug discovery. In transplantation, U.S. centers performed more than 48,000 organ transplants in 2024, each one requiring HLA typing of donor and recipient.
Deep repertoire sequencing and single-cell profiling remain expensive, and payer coverage is largely limited to MRD testing in specific blood cancers and HLA typing for transplantation, which slows clinical uptake and limits use in large studies and emerging economies. Turning repertoire data into therapeutics and diagnostics has also proved slow and uncertain. Data complexity is a further challenge: each person's repertoire holds millions of unique receptor sequences, HLA is one of the most variable gene regions in humans, and links between sequence, antigen specificity, and outcome are not fully understood. Clinical tests must also meet FDA, EU IVDR, and laboratory accreditation requirements, which raises development cost and time.
MRD testing offers a significant opportunity as it moves from academic centers into community oncology, from bone marrow to blood samples, and into more lymphoid cancers. Autoimmune disease is another major opening, with repertoire sequencing used to find disease-linked clones and monitor CAR-T and other cell therapies now in development for autoimmune conditions. Personalized cancer vaccines need tumor sequencing, HLA typing, and neoantigen prediction, and faster long-read typing can support deceased donor organ allocation. Key trends include the shift toward long-read HLA typing, portfolio refocusing through divestitures and business separations, and the use of AI to predict antigen specificity and HLA-peptide binding.
By offering, the immunogenomics market is segmented into kits & reagents, instruments, software & bioinformatics, and services (clinical testing services and research services). Kits & reagents are expected to account for the largest share in 2026, as HLA typing kits, repertoire library preparation kits, single-cell reagents, and sequencing chemistry are consumed with every sample in histocompatibility, clinical, and research laboratories. Services are expected to grow at the highest CAGR, driven by fast-rising clinical immunosequencing volumes, led by clonoSEQ, and by drug developers outsourcing repertoire and neoantigen work to specialist providers. Software & bioinformatics gains weight as interpreting data becomes as critical as generating it.
By technology, the immunogenomics market is segmented into short-read next-generation sequencing (NGS), long-read sequencing, PCR-based methods, single-cell sequencing, and other technologies. Short-read NGS is expected to account for the largest share in 2026, as it underpins clinical immunosequencing tests such as clonoSEQ, high-resolution HLA kits such as HybriType, and most research repertoire studies. Long-read sequencing is expected to grow at the highest CAGR, because it reads full-length HLA alleles, cuts phasing ambiguity in highly polymorphic genes, and allows fast typing for deceased donors, with new assays such as AlloSeq Nano reaching laboratories. PCR-based methods should grow more slowly as laboratories switch to sequencing, while single-cell sequencing is set for strong growth in research.
By analysis type, the immunogenomics market is segmented into HLA & KIR typing, immune repertoire sequencing (TCR and BCR sequencing), immune gene expression profiling, neoantigen & immunopeptidome analysis, and other analysis types. HLA & KIR typing is set to hold the largest share in 2026, as typing is routine in solid organ and stem cell transplantation, donor registries rely on it, and laboratories are moving to high-resolution sequencing-based typing. Immune repertoire sequencing is expected to grow at the highest CAGR, supported by rapid growth in MRD testing, TCR sequencing in immuno-oncology and cell therapy programs, and new uses in autoimmune and infectious diseases. Neoantigen and immunopeptidome analysis is set to benefit as personalized cancer vaccines advance through clinical trials.
By application, the immunogenomics market is segmented into oncology (hematologic malignancies & MRD and immuno-oncology & solid tumors), transplantation, autoimmune & inflammatory diseases, infectious diseases & vaccine research, and other applications. Oncology is expected to account for the largest share in 2026, reflecting strong growth in MRD testing for blood cancers and the heavy use of immune profiling in immuno-oncology discovery and drug programs. Autoimmune & inflammatory diseases are expected to grow at the highest CAGR, as repertoire sequencing helps identify disease-linked clones, cell therapies are being developed for autoimmune conditions, and research into the genetics of autoimmunity is expanding. Transplantation holds a significant share, supported by routine HLA typing and growing uptake of fast long-read methods.
By end user, the immunogenomics market is segmented into hospitals & clinical laboratories, histocompatibility laboratories & donor registries, academic & research institutes, pharmaceutical & biotechnology companies, and other end users. Hospitals & clinical laboratories are set to hold the largest share in 2026, as MRD tests and HLA typing are ordered as part of routine patient care for blood cancer and transplant patients. Pharmaceutical & biotechnology companies are expected to grow at the highest CAGR, driven by immunogenomic work in immuno-oncology, cell therapy, and vaccine programs and by the growing use of MRD as a trial endpoint. Histocompatibility laboratories and donor registries remain core buyers of HLA typing kits and software.
North America is set to hold the largest share of the immunogenomics market in 2026, owing to high use of clinical immunosequencing for MRD, many transplant centers and HLA laboratories, deep cell therapy and immuno-oncology research, and home-based suppliers such as Adaptive Biotechnologies, CareDx, Illumina, 10x Genomics, Invivoscribe, and Thermo Fisher Scientific. CareDx keeps an exclusive North American right to distribute post-transplant monitoring tests under its agreement with Eurobio Scientific, while Canada adds demand through transplant programs and academic research. Europe holds a significant share, backed by strong histocompatibility networks, active transplant programs, standards set through EFI, and suppliers including France-based Eurobio Scientific and Dutch firm GenDx; the leading national markets are the U.K., Germany, France, Italy, Spain, and the Netherlands.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to expanding transplant programs and donor registries, rising cancer incidence, and growing investment in immuno-oncology and cell therapy. China is expected to hold the largest share in the region, helped by a large cell therapy industry and wider transplant services, while strong growth is expected in Japan, where Takara Bio is based, and in South Korea, India, and Australia. Latin America, led by Brazil and Mexico, and the Middle East & Africa, where Saudi Arabia, the UAE, and Israel are investing in transplantation and genomic medicine, hold smaller shares.
The immunogenomics market is moderately consolidated, as a few companies lead clinical immunosequencing and HLA typing while sequencing platform makers, single-cell technology firms, reagent suppliers, bioinformatics companies, and service providers compete in other parts of the workflow. Competition centers on sensitivity and accuracy, resolution and speed, regulatory clearances and accreditation, reimbursement, ease of workflow, analysis software, and global support. CareDx reported in April 2026 that it had agreed to sell its Lab Products business, including its NGS and PCR HLA kits and AlloSeq Nano, to Eurobio Scientific for USD 170 million in cash, and Adaptive Biotechnologies plans to split its MRD and Immune Medicine businesses.
Key companies profiled in the report include Adaptive Biotechnologies Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), CareDx, Inc. (U.S.), Eurobio Scientific SA (France), Werfen S.A. (Immucor) (Spain), Invivoscribe, Inc. (U.S.), 10x Genomics, Inc. (U.S.), and Takara Bio Inc. (Japan).
The market spans kits, reagents, instruments, software, and services for analyzing immune system genes and their diversity. In scope are T-cell receptor (TCR) and B-cell receptor (BCR) repertoire sequencing, including clinical immunosequencing for minimal residual disease (MRD); HLA and killer-cell immunoglobulin-like receptor (KIR) typing by next-generation sequencing (NGS), long-read sequencing, and PCR; immune gene expression profiling; single-cell profiling that pairs receptor sequences with gene expression; neoantigen and immunopeptidome analysis; and the bioinformatics needed to interpret the results. Customers range from transplant and histocompatibility laboratories and donor registries to hospital laboratories, research institutes, and drug developers.
Adaptive Biotechnologies reported second-quarter 2026 MRD revenue of USD 66.2 million, up 33%, as clonoSEQ volume rose 43% to 36,111 tests, and now guides to 2026 MRD revenue of USD 268-278 million. The company also reported Immune Medicine revenue of just USD 5.4 million in the quarter, down 40% year over year, a sign that clinical testing has commercialized far faster than repertoire data for drug discovery. In transplantation, U.S. centers performed more than 48,000 organ transplants in 2024, each one requiring HLA typing of donor and recipient.
Market Dynamics
Clinical immunosequencing for MRD is a major driver of the immunogenomics market, because MRD status strongly predicts relapse and survival in myeloma, lymphomas, and acute lymphoblastic and chronic lymphocytic leukemia, and doctors and trial sponsors now use it to guide therapy and measure outcomes. Histocompatibility laboratories are replacing serological and low-resolution PCR typing with high-resolution NGS and long-read methods that improve donor-recipient matching and lower the risk of rejection and graft-versus-host disease. Thermo Fisher Scientific's One Lambda HybriType HLA Plus Typing Flex kit, launched in March 2025, reports at least 99.8% concordance with a workflow under 5.5 hours, and CareDx's nanopore-based AlloSeq Nano, shown at the European Federation for Immunogenetics (EFI) meeting in April 2026, types eleven HLA loci plus ABO in under three hours. Immuno-oncology and cell therapy programs add demand, as TCR sequencing tracks engineered T cells and responses to checkpoint inhibitors, while single-cell platforms link receptor specificity to cell function in research.Deep repertoire sequencing and single-cell profiling remain expensive, and payer coverage is largely limited to MRD testing in specific blood cancers and HLA typing for transplantation, which slows clinical uptake and limits use in large studies and emerging economies. Turning repertoire data into therapeutics and diagnostics has also proved slow and uncertain. Data complexity is a further challenge: each person's repertoire holds millions of unique receptor sequences, HLA is one of the most variable gene regions in humans, and links between sequence, antigen specificity, and outcome are not fully understood. Clinical tests must also meet FDA, EU IVDR, and laboratory accreditation requirements, which raises development cost and time.
MRD testing offers a significant opportunity as it moves from academic centers into community oncology, from bone marrow to blood samples, and into more lymphoid cancers. Autoimmune disease is another major opening, with repertoire sequencing used to find disease-linked clones and monitor CAR-T and other cell therapies now in development for autoimmune conditions. Personalized cancer vaccines need tumor sequencing, HLA typing, and neoantigen prediction, and faster long-read typing can support deceased donor organ allocation. Key trends include the shift toward long-read HLA typing, portfolio refocusing through divestitures and business separations, and the use of AI to predict antigen specificity and HLA-peptide binding.
Segment Analysis
The report analyzes the market by offering, technology, analysis type, application, end user, and geography, helping stakeholders identify the most attractive areas for investment, product development, and partnering.By offering, the immunogenomics market is segmented into kits & reagents, instruments, software & bioinformatics, and services (clinical testing services and research services). Kits & reagents are expected to account for the largest share in 2026, as HLA typing kits, repertoire library preparation kits, single-cell reagents, and sequencing chemistry are consumed with every sample in histocompatibility, clinical, and research laboratories. Services are expected to grow at the highest CAGR, driven by fast-rising clinical immunosequencing volumes, led by clonoSEQ, and by drug developers outsourcing repertoire and neoantigen work to specialist providers. Software & bioinformatics gains weight as interpreting data becomes as critical as generating it.
By technology, the immunogenomics market is segmented into short-read next-generation sequencing (NGS), long-read sequencing, PCR-based methods, single-cell sequencing, and other technologies. Short-read NGS is expected to account for the largest share in 2026, as it underpins clinical immunosequencing tests such as clonoSEQ, high-resolution HLA kits such as HybriType, and most research repertoire studies. Long-read sequencing is expected to grow at the highest CAGR, because it reads full-length HLA alleles, cuts phasing ambiguity in highly polymorphic genes, and allows fast typing for deceased donors, with new assays such as AlloSeq Nano reaching laboratories. PCR-based methods should grow more slowly as laboratories switch to sequencing, while single-cell sequencing is set for strong growth in research.
By analysis type, the immunogenomics market is segmented into HLA & KIR typing, immune repertoire sequencing (TCR and BCR sequencing), immune gene expression profiling, neoantigen & immunopeptidome analysis, and other analysis types. HLA & KIR typing is set to hold the largest share in 2026, as typing is routine in solid organ and stem cell transplantation, donor registries rely on it, and laboratories are moving to high-resolution sequencing-based typing. Immune repertoire sequencing is expected to grow at the highest CAGR, supported by rapid growth in MRD testing, TCR sequencing in immuno-oncology and cell therapy programs, and new uses in autoimmune and infectious diseases. Neoantigen and immunopeptidome analysis is set to benefit as personalized cancer vaccines advance through clinical trials.
By application, the immunogenomics market is segmented into oncology (hematologic malignancies & MRD and immuno-oncology & solid tumors), transplantation, autoimmune & inflammatory diseases, infectious diseases & vaccine research, and other applications. Oncology is expected to account for the largest share in 2026, reflecting strong growth in MRD testing for blood cancers and the heavy use of immune profiling in immuno-oncology discovery and drug programs. Autoimmune & inflammatory diseases are expected to grow at the highest CAGR, as repertoire sequencing helps identify disease-linked clones, cell therapies are being developed for autoimmune conditions, and research into the genetics of autoimmunity is expanding. Transplantation holds a significant share, supported by routine HLA typing and growing uptake of fast long-read methods.
By end user, the immunogenomics market is segmented into hospitals & clinical laboratories, histocompatibility laboratories & donor registries, academic & research institutes, pharmaceutical & biotechnology companies, and other end users. Hospitals & clinical laboratories are set to hold the largest share in 2026, as MRD tests and HLA typing are ordered as part of routine patient care for blood cancer and transplant patients. Pharmaceutical & biotechnology companies are expected to grow at the highest CAGR, driven by immunogenomic work in immuno-oncology, cell therapy, and vaccine programs and by the growing use of MRD as a trial endpoint. Histocompatibility laboratories and donor registries remain core buyers of HLA typing kits and software.
Regional Analysis
The report covers North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa, spanning 18 countries and four rest-of-region groups. The regional analysis of the immunogenomics market considers transplant activity, MRD adoption, cell therapy and immuno-oncology research, donor registry networks, reimbursement, and supplier presence.North America is set to hold the largest share of the immunogenomics market in 2026, owing to high use of clinical immunosequencing for MRD, many transplant centers and HLA laboratories, deep cell therapy and immuno-oncology research, and home-based suppliers such as Adaptive Biotechnologies, CareDx, Illumina, 10x Genomics, Invivoscribe, and Thermo Fisher Scientific. CareDx keeps an exclusive North American right to distribute post-transplant monitoring tests under its agreement with Eurobio Scientific, while Canada adds demand through transplant programs and academic research. Europe holds a significant share, backed by strong histocompatibility networks, active transplant programs, standards set through EFI, and suppliers including France-based Eurobio Scientific and Dutch firm GenDx; the leading national markets are the U.K., Germany, France, Italy, Spain, and the Netherlands.
Asia-Pacific is projected to post the highest CAGR through 2036, owing to expanding transplant programs and donor registries, rising cancer incidence, and growing investment in immuno-oncology and cell therapy. China is expected to hold the largest share in the region, helped by a large cell therapy industry and wider transplant services, while strong growth is expected in Japan, where Takara Bio is based, and in South Korea, India, and Australia. Latin America, led by Brazil and Mexico, and the Middle East & Africa, where Saudi Arabia, the UAE, and Israel are investing in transplantation and genomic medicine, hold smaller shares.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025, together with company profiles covering business and financial overviews, immunogenomics portfolios, strategic developments, and SWOT analyses.The immunogenomics market is moderately consolidated, as a few companies lead clinical immunosequencing and HLA typing while sequencing platform makers, single-cell technology firms, reagent suppliers, bioinformatics companies, and service providers compete in other parts of the workflow. Competition centers on sensitivity and accuracy, resolution and speed, regulatory clearances and accreditation, reimbursement, ease of workflow, analysis software, and global support. CareDx reported in April 2026 that it had agreed to sell its Lab Products business, including its NGS and PCR HLA kits and AlloSeq Nano, to Eurobio Scientific for USD 170 million in cash, and Adaptive Biotechnologies plans to split its MRD and Immune Medicine businesses.
Key companies profiled in the report include Adaptive Biotechnologies Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), CareDx, Inc. (U.S.), Eurobio Scientific SA (France), Werfen S.A. (Immucor) (Spain), Invivoscribe, Inc. (U.S.), 10x Genomics, Inc. (U.S.), and Takara Bio Inc. (Japan).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global immunogenomics market.
- Explains how MRD immunosequencing, high-resolution and long-read HLA typing, and cell therapy development are driving demand.
- Assesses the impact of test costs, limited reimbursement, data complexity, and regulatory requirements on adoption.
- Identifies high-growth opportunities across offering, technology, analysis type, application, end user, and region.
- Tracks autoimmune repertoire profiling, neoantigen prediction, and AI-based receptor analysis.
- Benchmarks leading companies by test menus, platforms, clinical evidence, partnerships, and portfolio moves.
- Supports product planning, laboratory investment, partnering, and market entry decisions for test developers, laboratories, drug developers, and investors.
Key Questions Answered
- How big is the global immunogenomics market today, and how will it grow through 2036?
- How is clinical immunosequencing for MRD changing the revenue mix of the market?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How fast will histocompatibility laboratories move from PCR-based to NGS and long-read HLA typing?
- Which offering, technology, analysis type, application, and end user segments will grow the fastest?
- How will autoimmune disease, cell therapy, and personalized cancer vaccines expand demand for immunogenomic analysis?
- What do recent divestitures and business separations mean for the competitive landscape?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and what strategies are they using?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Immunogenomics Market, by Offering
6. Immunogenomics Market, by Technology
7. Immunogenomics Market, by Analysis Type
8. Immunogenomics Market, by Application
9. Immunogenomics Market, by End User
10. Immunogenomics Market, by Geography
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Adaptive Biotechnologies Corporation
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- CareDx, Inc.
- Eurobio Scientific SA
- Werfen S.A.
- Invivoscribe, Inc.
- 10x Genomics, Inc.
- Takara Bio Inc.
